KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $14.1 billion.

  • Moderna's Liabilities and Shareholders Equity fell 23.21% to $12.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $51.0 billion, marking a year-over-year decrease of 23.48%. This contributed to the annual value of $14.1 billion for FY2024, which is 23.25% down from last year.
  • According to the latest figures from FY2024, Moderna's Liabilities and Shareholders Equity is $14.1 billion, which was down 23.25% from $18.4 billion recorded in FY2023.
  • Moderna's 5-year Liabilities and Shareholders Equity high stood at $25.9 billion for FY2022, and its period low was $7.3 billion during FY2020.
  • For the 3-year period, Moderna's Liabilities and Shareholders Equity averaged around $19.5 billion, with its median value being $18.4 billion (2023).
  • Per our database at Business Quant, Moderna's Liabilities and Shareholders Equity skyrocketed by 361.61% in 2020 and then decreased by 28.74% in 2023.
  • Yearly analysis of 5 years shows Moderna's Liabilities and Shareholders Equity stood at $7.3 billion in 2020, then soared by 236.23% to $24.7 billion in 2021, then climbed by 4.82% to $25.9 billion in 2022, then dropped by 28.74% to $18.4 billion in 2023, then fell by 23.25% to $14.1 billion in 2024.